Debjit Chattopadhyay
Stock Analyst at Guggenheim
(2.42)
# 2,327
Out of 4,784 analysts
81
Total ratings
45.83%
Success rate
-0.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debjit Chattopadhyay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLNO Soleno Therapeutics | Maintains: Buy | $70 → $81 | $71.99 | +12.52% | 2 | Mar 28, 2025 | |
| CNTA Centessa Pharmaceuticals | Reiterates: Buy | $28 | $14.59 | +91.91% | 6 | Mar 26, 2025 | |
| BEAM Beam Therapeutics | Reiterates: Buy | $78 | $22.21 | +251.19% | 2 | Feb 27, 2025 | |
| MAZE Maze Therapeutics | Initiates: Buy | $19 | $11.42 | +66.37% | 1 | Feb 25, 2025 | |
| RZLT Rezolute | Reiterates: Buy | n/a | $2.93 | - | 2 | Feb 10, 2025 | |
| DYN Dyne Therapeutics | Reiterates: Buy | n/a | $11.45 | - | 4 | Jan 24, 2025 | |
| QURE uniQure | Reiterates: Buy | n/a | $12.47 | - | 5 | Dec 11, 2024 | |
| PRME Prime Medicine | Reiterates: Buy | $18 | $1.99 | +804.52% | 3 | Dec 3, 2024 | |
| BNTC Benitec Biopharma | Reiterates: Buy | $17 | $13.43 | +26.58% | 2 | Dec 3, 2024 | |
| FOLD Amicus Therapeutics | Maintains: Buy | $13 → $15 | $8.43 | +77.94% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $70 → $65 | $31.15 | +108.67% | 3 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $558 | $492.69 | +13.26% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $36.99 | - | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $4.70 | +304.26% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $3.65 | +502.74% | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $130 → $175 | $183.92 | -4.85% | 3 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $21.76 | +37.87% | 1 | Jan 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $110 | $71.44 | +53.98% | 3 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $29 | $1.55 | +1,770.97% | 1 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $11 | $0.38 | +2,787.14% | 2 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $50 | $37.82 | +32.21% | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $268.46 | - | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $1.93 | +1,350.78% | 1 | Dec 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $170 | $8.07 | +2,006.57% | 1 | Oct 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $8.62 | +132.02% | 2 | Dec 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $221 | $70.41 | +213.88% | 4 | Aug 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $123 | $25.46 | +383.11% | 8 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $54 | $12.37 | +336.54% | 3 | Jul 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $60 | $1.50 | +3,900.00% | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $30.28 | - | 3 | Jun 26, 2017 |
Soleno Therapeutics
Mar 28, 2025
Maintains: Buy
Price Target: $70 → $81
Current: $71.99
Upside: +12.52%
Centessa Pharmaceuticals
Mar 26, 2025
Reiterates: Buy
Price Target: $28
Current: $14.59
Upside: +91.91%
Beam Therapeutics
Feb 27, 2025
Reiterates: Buy
Price Target: $78
Current: $22.21
Upside: +251.19%
Maze Therapeutics
Feb 25, 2025
Initiates: Buy
Price Target: $19
Current: $11.42
Upside: +66.37%
Rezolute
Feb 10, 2025
Reiterates: Buy
Price Target: n/a
Current: $2.93
Upside: -
Dyne Therapeutics
Jan 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $11.45
Upside: -
uniQure
Dec 11, 2024
Reiterates: Buy
Price Target: n/a
Current: $12.47
Upside: -
Prime Medicine
Dec 3, 2024
Reiterates: Buy
Price Target: $18
Current: $1.99
Upside: +804.52%
Benitec Biopharma
Dec 3, 2024
Reiterates: Buy
Price Target: $17
Current: $13.43
Upside: +26.58%
Amicus Therapeutics
Nov 7, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $8.43
Upside: +77.94%
Oct 9, 2024
Maintains: Buy
Price Target: $70 → $65
Current: $31.15
Upside: +108.67%
Aug 2, 2024
Maintains: Buy
Price Target: $450 → $558
Current: $492.69
Upside: +13.26%
Jun 28, 2024
Assumes: Neutral
Price Target: n/a
Current: $36.99
Upside: -
Apr 30, 2024
Initiates: Buy
Price Target: $19
Current: $4.70
Upside: +304.26%
Mar 26, 2024
Initiates: Buy
Price Target: $22
Current: $3.65
Upside: +502.74%
Feb 27, 2024
Maintains: Buy
Price Target: $130 → $175
Current: $183.92
Upside: -4.85%
Jan 18, 2024
Initiates: Buy
Price Target: $30
Current: $21.76
Upside: +37.87%
Sep 13, 2023
Reiterates: Buy
Price Target: $110
Current: $71.44
Upside: +53.98%
Nov 21, 2022
Maintains: Buy
Price Target: $43 → $29
Current: $1.55
Upside: +1,770.97%
Nov 11, 2022
Maintains: Buy
Price Target: $13 → $11
Current: $0.38
Upside: +2,787.14%
Oct 13, 2022
Upgrades: Buy
Price Target: $50
Current: $37.82
Upside: +32.21%
Jun 27, 2022
Downgrades: Neutral
Price Target: n/a
Current: $268.46
Upside: -
Dec 16, 2021
Initiates: Buy
Price Target: $28
Current: $1.93
Upside: +1,350.78%
Oct 5, 2021
Initiates: Buy
Price Target: $170
Current: $8.07
Upside: +2,006.57%
Dec 15, 2020
Assumes: Buy
Price Target: $20
Current: $8.62
Upside: +132.02%
Aug 31, 2020
Maintains: Buy
Price Target: $260 → $221
Current: $70.41
Upside: +213.88%
Aug 24, 2020
Downgrades: Neutral
Price Target: $270 → $123
Current: $25.46
Upside: +383.11%
Jul 9, 2020
Maintains: Buy
Price Target: $60 → $54
Current: $12.37
Upside: +336.54%
Dec 3, 2019
Downgrades: Neutral
Price Target: $60
Current: $1.50
Upside: +3,900.00%
Jun 26, 2017
Downgrades: Neutral
Price Target: n/a
Current: $30.28
Upside: -